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Abstract
Background: Patients with COVID-19 infection are commonly reported to have an increased risk of venous throm‑
bosis. The choice of anti-thrombotic agents and doses are currently being studied in randomized controlled trials
and retrospective studies. There exists a need for individualized risk stratification of venous thromboembolism (VTE)
to assist clinicians in decision-making on anticoagulation. We sought to identify the risk factors of VTE in COVID-19
patients, which could help physicians in the prevention, early identification, and management of VTE in hospitalized
COVID-19 patients and improve clinical outcomes in these patients.
Method: This is a multicenter, retrospective database of four main health systems in Southeast Michigan, United
States. We compiled comprehensive data for adult COVID-19 patients who were admitted between 1st March 2020
and 31st December 2020. Four models, including the random forest, multiple logistic regression, multilinear regres‑
sion, and decision trees, were built on the primary outcome of in-hospital acute deep vein thrombosis (DVT) and pul‑
monary embolism (PE) and tested for performance. The study also reported hospital length of stay (LOS) and intensive
care unit (ICU) LOS in the VTE and the non-VTE patients. Four models were assessed using the area under the receiver
operating characteristic curve and confusion matrix.
Results: The cohort included 3531 admissions, 3526 had discharge diagnoses, and 6.68% of patients developed
acute VTE (N = 236). VTE group had a longer hospital and ICU LOS than the non-VTE group (hospital LOS 12.2 days vs.
8.8 days, p < 0.001; ICU LOS 3.8 days vs. 1.9 days, p < 0.001). 9.8% of patients in the VTE group required more advanced
oxygen support, compared to 2.7% of patients in the non-VTE group (p < 0.001). Among all four models, the ran‑
dom forest model had the best performance. The model suggested that blood pressure, electrolytes, renal function,
hepatic enzymes, and inflammatory markers were predictors for in-hospital VTE in COVID-19 patients.
Conclusions: Patients with COVID-19 have a high risk for VTE, and patients who developed VTE had a prolonged hos‑
pital and ICU stay. This random forest prediction model for VTE in COVID-19 patients identifies predictors which could
aid physicians in making a clinical judgment on empirical dosages of anticoagulation.
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Introduction
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) has been causing COVID-19 illness
globally since December 2019, with more than 310 million people infected and more than five million deaths
reported as of 1st Jan 2022 [1]. The common manifestations of COVID-19 include fever, cough, dyspnea,
myalgia, fatigue, and diarrhea. Primarily, COVID-19
infection results in respiratory complications. However, it is evident that COVID-19 infection may be
associated with a hyper-coagulable state, which leads to
microvascular and macrovascular arterial and venous
thromboembolism (VTE) [2, 3].
The incidence of VTE complications in COVID-19
patients ranged from 1.7 to 16.5% in 35 observational
studies reported from around the world (total N = 9249)
[4]. Researchers postulated that a severely activated
inflammatory response to COVID-19 infection causes
thrombo-inflammation; through mechanisms such as
cytokine storm, complement activation, and endotheliosis [5]. In addition, certain studies reported findings
of microthrombi in autopsies of COVID-19 patients
[6]. Recent retrospective studies proposed several risk
factors associated with higher mortality and higher
severity of COVID-19, including inflammatory markers
such as interleukin-6 (IL-6), D-dimer, ferritin, and lactate dehydrogenase (LDH)[7, 8]. Moreover, many studies also showed VTE in COVID-19 is associated with
severity of infection and mortality [8]. Hence it is critical for physicians to identify the risk factors for the prevention and early management of VTE.
Most of the prediction models built for COVID19 patients predict prognosis [9–11], with only a few
models predicting VTE [12–14]. These models were
built using a limited selection of variables, mostly had
a smaller sample size, and primarily involved modification and validation of pre-COVID-19 VTE prediction
models. With the growing awareness of VTE risk in
COVID-19, patients are now routinely placed on prophylactic dose anticoagulants per National Institute
Health recommendation, except in cases of high bleeding risk, severe thrombocytopenia, or suspected hemorrhage necessitating caution in these selected patients
[6, 15–17]. This highlights the need for a prediction
model tailored for COVID-19 patients, with comprehensive variable selection and performance evaluation,
which can support the use of anticoagulation in this
crucial patient population. Therefore, we analyzed the

independent predictors of VTE using different machine
learning methods in a cohort of 3531 hospitalized
COVID-19 patients from Southeastern Michigan.

Methods
In this cross-sectional retrospective observational
study, we report and analyze the data from Southeastern Michigan COVID-19 Consortium Registry Database (SMCRD). As previously described, SMCRD is a
multi-institutional registry database of four main health
systems in Southeast Michigan, United States, including Henry Ford Health System, Beaumont Health System, Trinity Health System, and Wayne State University
[18]. It is built using REDCap and is housed at Vanderbilt University Medical Center. The SMCRD registry
contains de-identified data of adult patients who were
hospitalized with laboratory-confirmed SARS-CoV-2
PCR tests. Each institution independently collected
data from March 1, 2020, to September 5, 2021. Our
study was approved by the institutional review board
(IRB) of Trinity Health System.
Procedures

We compiled data for adult patients (age 18 years or
older) that included baseline demographics, laboratory results, and in-hospital events, including allcause mortality of COVID-19 patients from March 1,
2020, to the end of December 2020. All patients (with
and without VTE events) were included (Fig. 1). For
each patient, a total of 85 variables (Additional file 1:
Table S1) from six categories were extracted, including baseline demographics, presenting vital signs,
past medical history (abstracted using standard-text
variables, International Classification of Diseases–
Tenth Revision (ICD-10) and Current Procedural Terminology codes), social history, admission reasons,
pre-admission and in-hospital medications, hospital course, laboratory values, electrocardiogram, and
imaging studies (magnetic resonance imaging (MRI),
computerized tomography scan, ultrasounds). Variables in our study included: personal information (age,
sex, race/ethnicity, body mass index (BMI), social
history), hospital summary (hospital length of stay
(LOS), intensive care unit (ICU) admission and LOS,
use of oxygen devices, intubation status), laboratory
values (white blood cell (WBC) counts, D-dimer, ferritin, LDH, lactate, C-reactive protein (CRP), and so
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Total admissions
(N=12,688)

Included admission during
1st March - 31st December, 2020
(N=12,1278)

Excluded (N=8569)
1. Age <18 (N=78)
2. Only rapid COVID-19 posive result
(N=2172)
3. No sufficient lab, vital signs or
inpaent medicaon records (N=6397)
Included in analysis (N=3531)
1. First admission (N=3416)
2. 1st readmission (N=109)
3. 2nd readmission (N=6)
Fig. 1 Consort diagram of Southeastern Michigan COVID-19 Registry Consortium Database

on), past medical history, vital signs, and in-hospital
prophylactic and therapeutic anticoagulation therapy.
Since COVID-19 can cause VTE in patients following discharge, we followed patients after their initial
hospital discharge for readmission and development
of VTE. Accordingly, patients with one-time admission and readmissions, with or without thromboembolism events, were considered when building prediction
models.

Outcomes

The primary outcome was in-hospital VTE events,
including acute deep vein thrombosis (DVT) and pulmonary embolism (PE) identified by ICD-10 codes
(Additional file 1: Table S2), venous Doppler ultrasounds, ventilation-perfusion scan, and computed
tomography angiography (CTA) of the chest. In-hospital outcomes (Table 1) included mortality, and hospital
and ICU LOS.
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Table 1 Baseline characteristics of COVID-19 patients with and without acute venous thromboembolism
Variable

No VTE

Gender

Acute VTE

p value
1

Male

1447 (49.8)

118 (50.0)

Female

1460 (50.2)

118 (50.0)

American Indian or Alaskan Native 6 (0.2)

0 (0.0)

Asian or Pacific Islander

52 (1.8)

0 (0.0)

Black

995 (34.2)

93 (39.4)

White

1645 (56.6)

131 (55.5)

Hispanic

50 (1.7)

1 (0.4)

Others

86 (3.0)

4 (1.7)

Unknown

72 (2.5)

7 (3.0)

Age (years)

Mean (SD)

66.2 (16.4)

68.0 (16.7)

0.125

Body mass index (kg/m2)

< 18.5

52 (1.9)

7 (3.3)

0.329

18.5–24.9

487 (17.7)

44 (20.8)

25–29

828 (30.2)

60 (28.3)

> 30

1378 (50.2)

101 (47.6)

Hospital LOS (days)

Mean (SD)

8.8 (6.4)

12.2 (9.2)

< 0.001

Total ICU (days)

Mean (SD)

1.9 (5.0)

3.8 (8.1)

< 0.001

Mechanical ventilation (days)

Mean (SD)

Race/ethnicity

Cardiopulmonary resuscitation

Labs on presentation

1.1 (3.9)

2.4 (6.9)

0.005

420 (14.4)

37 (15.7)

0.675
< 0.001

None

2241 (77.4)

153 (64.8)

Nasal cannula/non-rebreather
mask

574 (19.8)

60 (25.4)

Ventilator

43 (1.5)

11 (4.7)

Other

29 (1.0)

5 (2.1)

High-flow nasal cannula

7 (0.2)

7 (3.0)

Mean (SD)

94.0 (6.2)

93.4 (7.2)

Heart rate (beats/minute)

94.3 (19.7)

100.7 (20.7)

< 0.001

Respiratory rate (breaths/minute)

20.9 (6.4)

21.3 (6.0)

0.283

Oxygen device

Vitals on presentation

0.119

Oxygen saturation (%)

0.258

Diastolic blood pressure (mmHg)

74.7 (15.6)

74.6 (16.5)

0.897

Systolic blood pressure (mmHg)

134.1 (24.9)

130.9 (25.6)

0.074

White blood cell count (K/uL)

7.5 (4.5)

9.4 (6.0)

< 0.001

Lymphocytes (K/uL)

1.6 (1)

1.4 (0.9)

0.007

Neutrophils (K/uL)

6.7 (2.5)

6.6 (2.8)

0.645

Hemoglobin A1c (%)

7.8 (2.2)

7.4 (2.2)

0.281
0.387

B-type natriuretic peptide (pg/mL)

167.2 (338.2)

189.5 (311.9)

C-reactive protein (mg/dL)

9.2 (7.6)

11.6 (8.5)

< 0.001

D-dimer (μg/mL)

1.8 (2.3)

4.6 (5.0)

< 0.001

Ferritin (ng/mL)

753.3 (1673.9) 725.7 (978.0)

0.716

Fibrinogen (mg/dL)

570.5 (168.3)

0.573

554.0 (207.1)

Interleukin-6 (pg/mL)

76.3 (127.4)

136.5 (159.8)

0.094

)Hemoglobin (gm/dL)

10.9 (2.9)

12.4 (5.1)

0.754

Lactate (mmol/L)

1.8 (1.4)

2.0 (1.3)

0.384

Lactate dehydrogenase (U/L)

322.9 (340.8)

370.1 (367.3)

0.079

Alanine transaminase (U/L)

53.1 (205.8)

64.5 (204.0)

0.436

Aspartate aminotransferase (U/L)

59.9 (216.8)

100.3 (564.9)

0.298

Procalcitonin (ng/mL)

2.1 (8.7)

1.3 (2.2)

0.008

Blood urea nitrogen (mg/dL)

26.0 (21.3)

30.3 (26.0)

0.018

Creatinine (mg/dL)

1.6 (2.0)

1.6 (1.9)

0.711

Potassium (meq/L)

4.0 (0.7)

4.1 (0.8)

0.034

Total bilirubin (mg/dL)

0.8 (0.6)

1.0 (2.6)

0.227

Platelet count (K/uL)

218.1 (95.3)

258.7 (144.2)

< 0.001
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Table 1 (continued)
Variable
Social history

In-hospital medications

Home medications

Oxygen requirement prior to admis‑
sion

Smoker

No VTE

Acute VTE

p value

216 (7.4)

19 (8.1)

0.826

Alcohol Use

45 (1.5)

7 (3.0)

0.168

Marijuana Use

18 (0.6)

3 (1.3)

0.443

Inpatient anticoagulation thera‑
peutic dose

302 (11.5)

101 (46.3)

< 0.001

Inpatient anticoagulation prophy‑
lactic dose

2446 (92.8)

162 (74.3)

< 0.001

Non-steroidal anti-inflammatory
drugs

29 (10.9)

5 (18.5)

0.384

Azithromycin

21 (7.9)

4 (14.8)

0.383

Hydroxychloroquine

4 (1.5)

1 (3.7)

0.949

Angiotensin-converting enzyme
inhibitors

66 (24.7)

9 (33.3)

0.455

Angiotensin—ll receptor blockers

42 (15.7)

5 (18.5)

0.919

Beta blockers

91 (34.1)

7 (25.9)

0.52

Diuretics

85 (31.8)

9 (33.3)

1

Statins

115 (43.1)

8 (29.6)

0.252

Warfarin

12 (4.5)

2 (7.4)

0.839

Aspirin

88 (33.0)

5 (18.5)

0.187

P2Y12 inhibitors

10 (3.7)

2 (7.4)

0.685

Direct-acting oral anticoagulants

17 (6.4)

0 (0.0)

0.359

Other anticoagulants

7 (2.6)

0 (0.0)

0.85

Corticosteroids

26 (9.7)

4 (14.8)

0.619

Proton pump inhibitors

70 (26.2)

10 (37.0)

0.329

Yes

18 (6.7)

0 (0.0)

0.319

Unknown

Lab values (Maximum and Minimum) White blood cell count Max
Lymphocytes Min

Mean (SD)

5 (1.9)

1 (3.7)

8.8 (5.3)

10.4 (6.2)

< 0.001

12.3 (7.6)

11.0 (7.5)

0.013

Neutrophils Max

84.0 (10.6)

86.0 (10.5)

0.007

Hemoglobin A1c Min

7.8 (2.2)

7.4 (2.2)

0.291

B-type natriuretic peptide Max

168.8 (333.9)

197.0 (318.8)

0.283

C-reactive protein Max

7.6 (5.8)

9.8 (8.1)

< 0.001

D-dimer Max

2.3 (2.5)

4.7 (3.8)

< 0.001

Ferritin Max

871.4 (2476.0) 773.6 (1094.9) 0.284

Fibrinogen Max

594.3 (168.9)

571.8 (196.6)

0.423

Interleukin-6 Max

79.3 (137.6)

138.3 (160.5)

0.104

Hemoglobin Min

10.0 (2.4)

10.6 (0.5)

0.445

Lactate Max

2.0 (1.5)

2.4 (2.7)

0.165

Lactate dehydrogenase Max

380.0 (369.0)

438.1 (378.4)

0.036

ICU intensive care unit, Max maximum, Min minimum, LOS length of stay, SD standard deviation, VTE venous thromboembolism

Statistical analysis
Initial data cleaning and analysis

Laboratory values at the time of admission, peak, and
minimum values were collected. For VTE, approximately
5% of patients had CTA chest images available, and 1%
of patients had CTA-confirmed PE and vessel image-confirmed DVT; limited diagnostic testing was likely due to

the COVID-19 hospitals’ policy of limiting exposure to
the virus in the first wave of the pandemic. Of the 3531
patients, 161 patients had PE, and 121 had DVT. 3127
patients were anticoagulated with either enoxaparin or
heparin. Enoxaparin dosage higher than 40 mg subcutaneous twice daily was considered as therapeutic dose
(N = 340), whereas less than 40 mg subcutaneous twice

Lee et al. BMC Infectious Diseases

(2022) 22:462

daily was defined as prophylactic dose (N = 1920). Intravenous heparin was included in the therapeutic dose
(N = 182) and subcutaneous heparin was considered as
the prophylactic dose (N = 1315). In total, 1018 patients
received therapeutic dose and 2976 patients received
prophylactic dose anticoagulation.
We categorized race/ethnicity, BMI, oxygen devices,
smoking, alcohol and marijuana history, and past medical history into dichotomous variables, while laboratory test values were retained as continuous variables.
Initial descriptive analysis for continuous variables was
described as mean with standard deviation or median
with interquartile range. Categorical variables were
described as frequency distributions. To compare the
groups, the Chi-square test was used for categorical variables, and the t-test was used for continuous variables.
Univariate analysis and principal component analysis
(PCA) were used to identify potential risk factors for
VTE (Additional file 1: Table S3 and Fig. S1). All data
were analyzed using SAS v9.4 or R 3.6.2, and a p-value
less than 0.05 was considered to indicate statistical significance. Prediction models were built using JMP Pro
14.2.0 (Additional file 1: Table S4).
Data cleaning

As part of exploratory data analysis, the distribution of
all the variables was plotted. Most laboratory values were
either left or right-skewed. Multiple variables could be
highly correlated with each other and potentially result in
interactions in the process of model building. For example, both neutrophil and lymphocyte counts comprise
the neutrophil–lymphocyte ratio. Likewise, BUN and
creatinine comprise the BUN-creatinine ratio, which is
a parameter that could indicate different types of acute
kidney injury; for example, the BUN-creatinine ratio > 20
suggests pre-renal acute kidney injury. Therefore, Spearman’s rho was performed. Twenty-three groups of variables that were highly positively or negatively correlated
based on Spearman’s coefficient of more than ± 0.7
(Additional file 1: Table S5A) were aspartate aminotransferase (AST) and alanine transaminase (ALT), creatinine
and BUN, maximum (max) B-type natriuretic peptide
(BNP) and initial BNP, max CRP and initial CRP, max ferritin and initial ferritin, max D-dimer and initial D-dimer,
neutrophil–lymphocyte ratio and neutrophils, max neutrophils and minimum lymphocyte, history of VTE, DVT
and PE, systolic blood pressure and diastolic blood pressure, inpatient therapeutic anticoagulation and inpatient
prophylactic anticoagulation and so on. Therefore, we
downsized the variables; for example, neutrophil and
lymphocyte alone were analyzed in the model building
rather than the neutrophil–lymphocyte ratio. Likewise,
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BUN and creatinine alone were included rather than the
BUN-creatinine ratio; the history of VTE was used rather
than its components (DVT and PE) (Additional file 1:
Table S5B). When building models, we used lab values
on admission rather than the peak or lowest values as we
aimed to build a prediction model which can assist physicians in predicting VTE in COVID-19 patients on admission based on the available data. The PCA was performed
to reduce the dimensions used to predict VTE events.
Patients without missing data (N = 1443) from the cohort
were included in the PCA. A total of 32 continuous variables were included in the PCA. In the scree plot, the 1st
component explained only about 16% of variations of the
data, and only 24.6% of the variations were explained by
the first two components (Additional file 1: Table S3 and
Fig. S1). Therefore, the PCA was deemed not helpful in
reducing the dimensions in our analysis. For both continuous and categorical variables, we further performed
univariate analysis using the R packages (Additional
file 1: Table S4).
Model building

The cohort was randomly split into the training set and
test set (70:30) multiple times. We compared four models
in their predictive accuracy for detecting VTE events and
mortality:
•
•
•
•

Multiple linear regression (MLR)
Multiple logistic regression (LR)
Decision tree
Random forest

Results
A total of 3531 admissions were identified, of which 3416
were first admissions and 115 were readmissions; of the
115 readmitted patients, 109 were readmitted once, and
6 were readmitted twice. Overall, there were 236 patients
(6.68%) with VTE events and 2907 patients with no VTE
events in the dataset. In general, the VTE group had
a longer LOS in hospital and ICU than the non-VTE
group (hospital LOS 12.2 days vs. 8.8 days, p < 0.001; ICU
LOS 3.8 days vs. 1.9 days, p < 0.001). In addition, 9.8%
of patients in the VTE group required advanced oxygen
support, compared to 2.7% of patients in the non-VTE
group (p < 0.001). Laboratory values such as WBC, CRP,
D-dimer, and platelet count were significantly different
between VTE and non-VTE groups (p < 0.001). Baseline
demographic characteristics of patients are summarized
in Table 1. The mean age for VTE and non-VTE patients
was 68 ± 16.7 years and 66.2 ± 16.4 years (p = 0.125),
respectively. Morbid obesity was common in both groups
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(VTE vs. non-VTE: 47.6% vs. 50.2%, p = 0.329). The inhospital all-cause mortality for VTE patients was 22.2%,
whereas non-VTE patients was 14.8% [Odds ratio (OR):
1.65, 95% confidence interval (CI): 1.22, 2.22, p = 0.001].
We also found that the VTE group had a longer hospital
LOS, ICU LOS, and days on ventilator than the non-VTE
group. The univariate analysis of predictors of VTE upon
admission are shown in Additional file 1: Table S3. The
variables like IL-6 (pg/mL), CRP (mg/dL), D-dimer (ng/
mL), WBC (K/uL), BUN (mg/dL) had an OR of 1.00 to
1.2 and were significant; this was not negligible as most of
the variables were measured on a small scale. Moreover,
these laboratory variables are of great interest in COVID19 patients because COVID-19 infection causes cytokine
storm leading to elevated inflammatory markers, such
as ferritin, LDH, CRP, and IL-6. These inflammatory
responses result in endotheliitis and hypercoagulopathy
that predispose the patients to develop VTE.
Prediction model for VTE

The most significant variables of each model are shown
in Table 2. For MLR and LR, the significant variables
were selected based on the p-value of < 0.05; for decision tree and random forest, they were based on the
Gini index. MLR was eliminated as it is not ideal for
categorical variables. The decision tree has worse accuracy than a random forest but provides interpretability. Our decision tree was firstly split by the root node
as therapeutic anticoagulation as inpatient, followed
by leaf nodes of BUN (< 20, 20), hospital LOS (< 20,
20), Age (< 91, 91), race (White, non-White), D-dimer
(4740 ng/mL, < 4740 ng/mL), history of VTE, and
D-dimer (2170 ng/mL, < 2170 ng/mL) (Additional file 1:
Fig. S2). Whereas random forests are an ensemble of
decision trees that solve the overfitting of the decision
tree as the predictions are based on an average of all
trees. On the other hand, loss of interpretability is one
of the limitations of the random forests. Both decision
trees and random forests handle continuous and categorical variables that best analyze our cohort. Across
all models, D-dimer was the most significant variable
for MLR, LR, and decision tree models. Other common variables across the models include VTE history,
inpatient therapeutic anticoagulation, requirement for
oxygen devices such as high-flow nasal cannula, nonrebreather mask, and mechanical ventilation, heart
rate, BUN, and so on. The four models were compared,
as shown in Table 3, to analyze predictive ability in
diagnosing COVID-19 associated VTE. Random forest
performed the best among all in terms of R-square ( R2),
misclassification rate, and receiver operating characteristic (ROC) curve.
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Performance of the model

Random forest model consisted of 22 variables (significance in order): D-dimer, inpatient therapeutic anticoagulation therapy, platelet count, BUN, age, WBC, systolic
blood pressure, lymphocytes, ALT, potassium, BNP, CRP,
creatinine, LDH, neutrophils, heart rate, total bilirubin,
AST, diastolic blood pressure, prior history of VTE, ferritin, and oxygen saturation on admission. Electrolytes,
renal function, blood pressures, hepatic enzymes, and
inflammatory markers were indicators of VTE risks. The
evaluation of the performance and confusion matrix of
the four models in training and the validation process is
shown in Table 3. The R
 2 of the random forest model for
the training and validation set was 58.87% and 18.76%
(p < 0.0001); the area under the ROC curve was 0.83
(Fig. 2). We set a cutoff of 0.1 for the generation of sensitivity and specificity. The random forest model had a sensitivity of 0.68 and a specificity of 0.82. In our cohort, the
classification was skewed; therefore, the default threshold
(0.5) cannot represent an optimal interpretation of the
predicted probabilities. Effectively, our goal was to provide a robust model for clinicians to identify COVID-19
patients at risk for VTE early in the hospital course and
assist in deciding between therapeutic versus prophylactic anticoagulation management. In the validation set, the
model showed that it was good at predicting the absence
of a venous event more than the presence of a venous
event. The negative predictive value (NPV) and positive
predictive value (PPV) of the model for the validation set
were 0.97 and 0.26. Due to the low prevalence of VTE in
the population, the F1 score of the model was calculated
as 0.35.

Discussion
VTE is one of the most common complications in
COVID-19 patients [19–22]. This retrospective study
presents a prediction model for VTE in COVID-19
patients and the demographics, clinical parameters, and
incidence rate of VTE in COVID inpatients. The incidence rate of VTE could have been underreported due
to limited radiological testing to reduce staff exposure
to COVID-19 infection in the first wave [23]. Our study
reported an incidence rate of 6.68%, similar to other studies [24–29] (Table 4). We found that patients who developed new-onset VTE had more extended hospital LOS
(12.2 days vs. 8.8 days, p < 0.001) and ICU LOS (3.8 days
vs. 1.9 days, p < 0.001) compared to patients who did not
have VTE. This is a robust prediction model for VTE
in hospitalized patients with COVID-19 using a large
multicenter database (N = 3531). We included 85 variables from a broad spectrum of parameters, demographics, vitals, comorbidities, and hospital course (oxygen
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Table 2 Significant variables in prediction models, listed in descending order: (1) Multiple linear regression (2) Multiple logistic
regression (3) Decision tree (4) Random forest
Multiple linear regression

Multiple logistic regression

Decision tree

Random forest

D-dimer

D-dimer

Therapeutic anticoagulation
inpatient

D-dimer

Nonalcoholic steatohepatitis

History of venous thromboembo‑
lism

History of venous thromboembo‑
lism

Therapeutic anticoagulation
inpatient

History of venous thromboembo‑
lism

Mechanical ventilation

D-dimer

Platelet count

Therapeutic anticoagulation
inpatient

Therapeutic anticoagulation
inpatient

Age

Blood urea nitrogen

High-flow nasal Cannula

High-flow nasal Cannula

Race/ethnicity

Age

Mechanical ventilation

Nonalcoholic steatohepatitis

Blood urea nitrogen

WBC count

Coronary artery bypass graft

Nonalcoholic steatohepatitis

Hospital length of stay

Systolic blood pressure on presenta‑
tion

Heart rate on presentation

Thyroid disease

Lymphocytes

Alanine aminotransferase

Nasal Cannula or non-rebreather
Mask

Alanine aminotransferase

Chronic kidney disease

Coronary artery bypass graft

Abnormal potassium level (higher
or lower)

Chronic kidney disease

B-type natriuretic peptide

Ferritin

C-reactive protein
Creatinine
Lactate dehydrogenase
Neutrophils
Heart rate on presentation
Total bilirubin
Aspartate transaminase
Diastolic blood pressure on pres‑
entation
Venous thromboembolism
Ferritin
Oxygen saturation on presentation

requirement, ICU admission, hospital and ICU LOS).
Electrolytes, renal function, blood pressures, hepatic
enzymes, and inflammatory markers were indicators of
VTE risks; however, further studies on whether a cutoff
value could be applied to inflammatory markers for good
sensitivity and specificity for VTE in COVID-19 infection
would be beneficial. Physicians can assess patients’ presenting signs, renal and hepatic functions, and potentially
identify patients at high risk of VTE and work on the
reversible risk factors to reduce patients’ risks of developing VTE during hospitalization.
It is worth mentioning that we used presenting data
which was the initial data of patients admitted to the
hospital. Models such as multiple LR models that do not
handle missing data have smaller sample sizes that can
potentially affect performance. Our MLR model has an R2
of 0.2569, p < 0.0001. The R
 2 value of MLR and LR is low,
which is consistent with the fact that we did not include
laboratory values that are missing and did not impute

those values. The decision tree has a lower R2 value (0.19
in training and 0.11 in the testing set). However, the R
2
value is most likely not appropriate for a tree-based
model. Nevertheless, the random forest model has a low
misclassification rate (6.87% in the training set, 8.4% in
the testing set). Overall, we have low R
 2 values. The decision tree may have worse accuracy than a random forest,
but the tree structure is easy to understand and interpret.
By looking at the splitting nodes, key factors can be identified, and predictions can be made. On the other hand,
random forests are an ensemble of decision trees, and the
predictions are based on an average of all trees, which is
a “black box” that can’t be directly described. One of the
possibilities is that our study cohort has an inherently
higher amount of unexplainable variability; this could be
better addressed in future prospective studies.
Of 3532 records, only 1282 patients were included in
the MLR model due to the missing values in the other
patients. Similarly, in the LR, only 1282 records were
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Table 3 Model performance for venous thromboembolism prediction in COVID-19 patients
Model

Misclassification Rate R-square
TS

VS

AIC

TS

VS

BIC

Sensitivity

Specificity

PPV

NPV

AUC

Multiple linear regression

NA

NA

25.39%

16.29%

50

355

NA

NA

NA

NA

NA

Multiple logistic regression

5.74%

9.64%

41.12%

3.79%

436

742

0.76

0.76

0.87

0.85

0.80

Decision tree

7.11%

9.65%

19.89%

11.35%

NA

NA

0.69

0.65

0.78

0.79

0.77

Random forest

6.84%

8.40%

58.89%

18.76%

NA

NA

0.68

0.82

0.26

0.97

0.83

AIC Akaike information criterion, AUC area under the curve, BIC Bayesian information criterion, NA not applicable, NPV negative predictive value, PPV positive
predictive value, TS training set, VS validation set

used, which was less than 50% of the records. Although
IL-6, LDH, procalcitonin, ferritin, and fibrinogen were
excluded in the model building due to significant numbers of missing values, we found no significant difference
in these values between non-VTE and VTE groups.
Our model can provide clinical risk stratification
of VTE in COVID-19 patients and help individualize
thromboprophylaxis, which supports the current consensus of customized and risk-adapted management for
thromboprophylaxis in international guidelines [30]. Five
papers studied VTE in COVID-19 patients using existing prediction models [26, 31–34] (Table 5). Kampouri
et al. combined the Wells score and D-dimer value to
predict VTE with a PPV of 18.2%, an NPV 98.5%, and
accuracy of 0.905 [31]. A Dutch study reported a 41.7%
incidence rate of VTE in COVID-19 patients and built
a linear regression model consisting of D-dimer > 9 μg/
mL and CRP > 280 mg/mL, and the authors report a predicted probability of 92% [32]. Another study by Taplin
et al. modified the Caprini score using a cutoff value of
12, which is also based on the D-dimer score and showed
a sensitivity of 73% and specificity of 84% in predicting
VTE [33]. Unlike our study, most of these studies had a
smaller sample size and number of events and included
risk factors not analyzed in the original prediction model
studies. Notably, the performance of the model depends
on the event prevalence. Among all studies, the Dutch
study had the highest predictive probability in the critically ill population due to a higher incidence of VTE [32].
A meta-analysis of 47 studies showed high prevalence of
PE with high mean D-dimer values (prevalence ratio 1.3
per 1000 ng/mL increase; 95% CI: 1.11, 1.50, p = 0.002)
and percentage of ICU patients (1.02 per 1% increase;
95% CI: 1.01, 1.03, p < 0.001). In addition, prevalence
of DVT was also high across studies with high mean
D-dimer values (1.04 per 1000 ng/mL increase; 95% CI:
1.01, 1.07, p = 0.022)[35].
After systemic review, we included six studies that
reported VTE incidence rate in COVID-19 patients without prediction models (Table 4). Our study showed an
incidence rate of 6.68% of VTE in COVID-19 patients,
which is consistent with three of the studies [25, 28, 29],

Fig. 2 Receiver operating characteristic (ROC) curve of the random
forest model for venous thromboembolism in COVID-19 patients. The
random forest model’s area under the ROC curve was 0.83

whereas Freund et al. reported a rate of 15% and two
studies showed a lower incidence rate of 2–3% [24, 26,
27]. Critically ill COVID-19 patients who were admitted to ICU had a higher incidence rate of VTE. Only two
studies identified risk factors for COVID-19 patients
using the MLR model, including advanced age, increased
Charlson Comorbidity Index, history of cardiovascular
disease, ICU admission, elevated D-dimer, male gender,
heart rate, clinical signs of DVT, and recent immobilization [24, 26]. Unlike other studies, we did not impute
missing values to better build a model that predicts VTE
individually.
Our study analyzed D-dimer, lactate, and inflammatory
markers, including CRP, ferritin, and LDH that are of great
interest in clinical settings and have been routinely ordered
for COVID-19 patients. The utilization of laboratory values varies; many physicians trend these markers to predict
the trajectory of COVID-19 patients. However, limited
studies included them for VTE analysis. Our result showed

United States

Denmark

France, Spain,
Belgium, Italy, Chile,
Canada

China

France

China

Cohen et al.

Dalager- Pedersen
et al.

Freund et al.

Mei et al.

Poissy et al.

Rieder et al.

1540

9407

616

Retrospective, March 26th to 49
April 20th, 2020

Retrospective case series,
196 (ICU patients only)
February 27th to March 31st,
2020

Retrospective, January 1st to
March 23rd, 2020

6.1%

6.1% (PE only)

2% VTE (DVT and/or PE)

15% (only PE, DVT not
studied)

5% VTE (both ICU and gen‑
eral ward)

2.9% (2.4% in medical ward
and 4.9% in ICU)

Spearman test

The level of D-dimers at hos‑
pital admission and the maxi‑
mum level during follow-up
were correlated with days at
the hospital, days in ICU, days
on non-invasive ventilation, or
days on invasive ventilation

None

This study compared Padua
score in COVID-19 pneumonia
and community-acquired
pneumonia

χ2 test, Fisher exact test, t
test, and Mann–Whitney
U test
Simple descriptive analysis

1. Male gender
2. Age > 48
3. Heart rate
4. Prior history of VTEs
5. Clinical signs of DVT
6. Recent immobilization

This Study compared COVID19 and non-COVID-19 patients
showed COVID-19 patients had
a higher risk of VTE

For VTE or mortality:
1.Advanced age
2.Increasing Charlson Comor‑
bidity Index
3.History of cardiovascular
disease
4.ICU level of care, and
5.Elevated maximum D-dimer
with a cutoff at least four times
the upper limit of normal

Identified predictors

Multivariable binary logistic
regression

30-day absolute risks

Multivariate analysis

Total number of cases Venous thromboembolism Analysis performed
incidence rate

Retrospective, February 1st to 974
April 10th, 2020

Retrospective, January 27th
to June 1st, 2020

Retrospective, March 1st to
April 27th, 2020

Study type, time period

DVT deep vein thrombosis, ICU intensive care unit, PE pulmonary embolism, VTE venous thromboembolism

Country

Study

Table 4 Characteristics of retrospective COVID-19 studies on venous thromboembolism incidence rate and predictors
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Table 5 Characteristics of retrospective studies on venous thromboembolism prediction models
Study

Country

Study type, time
period

Total number of
cases

Venous
thromboembolism
incidence rate

Prediction model

Performance

Kampouri et al.

Switzerland

Retrospective,
February 28th to
April 30th, 2020

491

9.3%

Wells score for
PE ≥ 2 points
and D-dimer
value ≥ 3,000 ng/
mL

PPV: 18.2%
NPV: 98.5
Accuracy: 0.905

Dujardin et al.

Netherlands

Retrospective,
127
March 13th to April
9th, 2020

41.7%

Binary linear
regression model;
D-dimer is > 9 μg/
mL and C-reactive
protein > 280 mg/
mL

Predicted probabil‑
ity: 92%

Tsaplin et al.

Russia

Retrospective, April 168
30th to May 29th,
2020

6.5%

Modified Caprini
score > 12;
D-dimer > 3 upper
limit of normal

Sensitivity: 73%;
Specificity: 84%

Spyropoulos et al.

United States

Retrospective,
March 1st, 2020 to
April 27th, 2020

2.9%

The International
AUC: 70%; sensitivity:
Medical Prevention 97%; specificity: 22%
Registry on Venous
Thromboembo‑
lism and D‐Dimer
(IMPROVE‐DD) risk
assessment model

Freund et al.

France, Spain, Bel‑
gium, Italy, Chile,
and Canada

Retrospective, Feb‑ 974
ruary 1st to April
10th, 2020

15%

Revised Geneva
score and D-dimer
[D-dimer below
the age-adjusted
threshold (i.e.,
500 µg/mL under
50 years and
age × 10 over
50 years)]

9407

AUC: 0.81

AUCarea under the curve, NPV negative predictive value, PE pulmonary embolism, PPV positive predictive value

no significant difference in presenting CRP, IL-6, and
LDH levels among VTE and non-VTE groups (Table 1),
yet the maximum value of D-dimer, CRP, and LDH were
significantly higher in VTE groups. This may suggest that
D-dimer, CRP and LDH could be utilized clinically for
monitoring. However, further studies on the threshold,
sensitivity, and specificity of certain markers are needed.
Current guidelines by the American Society of Hematology (ASH) suggest using prophylactic-intensity over
intermediate-intensity anticoagulation for patients with
COVID-19 related critical illness who do not have suspected or confirmed VTE [36]. Furthermore, ASH suggests that an individualized assessment of the patient’s
risk of thrombosis and bleeding is important when deciding on anticoagulation intensity. Our study provides physicians with a model that could aid in risk stratification,
as VTE has been well-known to be a common COVID-19
complication.
We observed that 11.5% of patients (N = 302) who did
not have VTE were given a therapeutic dosage of anticoagulation, whereas 46.3% (N = 101) with VTE received

therapeutic anticoagulation. It is unclear why after diagnosis of VTE, over half of the patients only received prophylactic anticoagulants. It described an unmet need for
risk stratification for COVID-19 patients. Vaughn et al.
reported that 16.2% of patients who had suspected VTE
were given therapeutic anticoagulation and increased
treatment-dose anticoagulation for VTE prophylaxis
[37]. The INSPIRATION trial did not show the difference
in routine empirical use of intermediate-dose prophylactic anticoagulation compared to standard dose in ICU
patients with the primary composite outcome including
acute VTE, arterial thrombosis, the use of extracorporeal
membrane oxygenation, and all-cause mortality [absolute
risk difference, 1.5% (95% CI: − 6.6, 9.8); OR: 1.06 (95%
CI: 0.76, 1.48); p = 0.70] [16]. The Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATT
ACC
) randomized multicenter adaptive design trials
have shown therapeutic anticoagulation to be beneficial
in moderately ill patients, whereas it was futile in ICU
patients requiring organ failure support [38, 39].
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Our study has both strengths and limitations. The
strengths include the large sample size, multi-institutebased data, and availability of broad outcomes events
data. Moreover, our VTE prediction model in COVID19 patients can most benefit clinical practice to aid clinical management in settings where a definitive diagnosis
of VTE is hard to obtain, for example, for critically ill
patients on mechanical ventilation who are unable to
undergo CTA chest study. Since this is a retrospective
study utilizing a large database, we were unable to obtain
the timing of diagnosis of acute VTE in our cohort, which
would have allowed exploration of the temporal relationship between VTE and potential risk factors, highlighting an important limitation of our study. Furthermore,
although our models showed good predictive capacity,
the lower incidence of VTE in the population study created significant hurdles. The random forest model’s PPV
is 26%, NPV is 97%, and the F1 score is 0.36. Future studies on a composite outcome including both venous and
arterial events could provide a bigger population. Also,
the random forest model is not a panelized method and
has the risk of overfitting. Lastly, our model needs to be
validated externally.

Conclusions
There is a high incidence of VTE in hospitalized COVID19 patients. Prolonged hospital and ICU stay was noted
in patients who developed VTE. This random forest prediction model for VTE in COVID-19 patients is based on
a broad spectrum of parameters available on initial presentation and comorbidities. Factors like D-dimer, LDH,
platelet count, age, WBC, AST, ALT, BUN and creatinine,
heart rate on presentation, and prior history of VTE can
predict in-hospital VTE events which could aid physicians in making a clinical judgment on the empirical dosage of anticoagulation.
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